On January 24, the Central Epidemic Command Center (CECC) announced that the first batch of the oral antiviral Molnupiravir, doses for 2,016 patients to complete their course of treatment, Taiwan purchased from U.S. pharmaceutical company Merck arrived this morning. After customs clearance, the batch of the drug will be allocated to hospitals which can use the drug to treat patients at risk of severe illness and diagnosed with mild to moderate COVID-19 symptoms to reduce medical care burden.

Please click here to see further details.